US Pharma MarketingFDA approves Viridian eye drug, stoking competition with Amgen
FDA approves Viridian Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals:…
The FDA approved Viridian Therapeutics' thyroid eye disease drug veligrotug, kicking off a competition with Amgen’s blockbuster Tepezza.
Viridian’s drug, to be marketed as Lumvoa, will be priced “in line with” Tepezza, CEO Steve Mahoney ...
Source: Endpoints News